P1, N=18, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

4 days ago

Trial completion date • Trial primary completion date

Venclexta (venetoclax) • cisplatin • gemcitabine • dexamethasone • Rituxan Hycela (rituximab/hyaluronidase) • Monjuvi (tafasitamab-cxix) • Columvi (glofitamab-gxbm)

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial (clinicaltrials.gov)

P1/2, N=27, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting

5 days ago

Enrollment open

TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • PAX5 (Paired Box 5) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • SOX11 (SRY-Box Transcription Factor 11) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)

TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A deletion

Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)

A prospective, multicenter, single-arm clinical study to evaluate the efficacy and safety of glofitamab in combination with gemcitabine, dexamethasone, and cisplatin (Glofit-GDP) as salvage therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (ChiCTR2600116920)

P=N/A, N=43, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University

6 days ago

New trial

cisplatin • gemcitabine • dexamethasone • Columvi (glofitamab-gxbm)

Immuno and targeted therapy for Richter transformation to diffuse large B-cell lymphoma (ChiCTR2500109894)

P2, N=34, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

6 days ago

New P2 trial

CD20 (Membrane Spanning 4-Domains A1) • PD-1 (Programmed cell death 1)

CD20 positive

lenalidomide • Tevimbra (tislelizumab-jsgr) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Columvi (glofitamab-gxbm)

21d

T-cell engaging antibodies for B-cell lymphomas. (PubMed, Semin Hematol)

This review focused on 4 CD20 × CD3 BsAbs, as well as surovatamig, a CD19 × CD3 BsAb currently under investigation that has demonstrated promising efficacy against relapsed/refractory B-cell lymphomas. All 4 CD20 × CD3 BsAbs are approved as third-line and beyond therapies: mosunetuzumab for follicular lymphoma (FL), glofitamab for diffuse large B-cell lymphoma (DLBCL), and epcoritamab and odronextamab for both FL and DLBCL (the latter in European Union only)...Multiple studies are currently evaluating these agents in both the relapsed/refractory and frontline settings, either as monotherapy or in combination with other agents. This review summarizes the efficacy and safety of each agent across B-cell lymphoma subtypes, along with their dosing schedules and CRS mitigation strategies.

21 days ago

Journal

CD20 (Membrane Spanning 4-Domains A1)

Epkinly (epcoritamab-bysp) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • Ordspono (odronextamab) • surovatamig (AZD0486)

23d

Glofitamab in Real Life (clinicaltrials.gov)

P=N/A, N=250, Recruiting, The Lymphoma Academic Research Organisation | Not yet recruiting --> Recruiting | Trial completion date: Nov 2026 --> Jul 2026 | Initiation date: Aug 2025 --> Dec 2025 | Trial primary completion date: Nov 2025 --> Mar 2026

23 days ago

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date

Columvi (glofitamab-gxbm)

28d

Glofitamab Combined With CAR-T Therapy in R/R DLBCL (clinicaltrials.gov)

P2, N=24, Not yet recruiting, Ruijin Hospital

28 days ago

New P2 trial

TP53 (Tumor protein P53)

TP53 mutation

Gazyva (obinutuzumab) • Yescarta (axicabtagene ciloleucel) • Carteyva (relmacabtagene autoleucel) • Columvi (glofitamab-gxbm)

29d

STARGLO: A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)

P3, N=270, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Feb 2026 --> Mar 2028 | Trial primary completion date: Feb 2026 --> Mar 2028

29 days ago

Trial completion date • Trial primary completion date

gemcitabine • Rituxan (rituximab) • Gazyva (obinutuzumab) • oxaliplatin • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)

Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma. (PubMed, J Clin Exp Hematop)

BsAbs targeting CD20/CD3, such as epcoritamab, glofitamab, mosunetuzumab, and odronextamab, are rapidly progressing toward widespread clinical application. Although monotherapy remains the standard approach, clinical trials are exploring earlier-line use and combination strategies to further enhance outcomes. Particular attention is given to predictive biomarkers of response and mechanisms of resistance, including target antigen loss, tumor histology, prior therapies, intratumoral and peripheral T-cell status, and the emerging role of minimal residual disease monitoring.

1 month ago

Review • Journal

CD20 (Membrane Spanning 4-Domains A1)

Epkinly (epcoritamab-bysp) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • Ordspono (odronextamab)

2ms

SKYGLO: An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (clinicaltrials.gov)

P3, N=1130, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

2 months ago

Enrollment closed

CD20 (Membrane Spanning 4-Domains A1)

CD20 positive

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)